Caterina de Luca

Feb 2, 2024 | onlinelibrary.wiley.com | Anna Maria Carillo |Caterina de Luca |Pasquale Pisapia |Elena Vigliar

1 OVERVIEW OF THE CHALLENGING SCENARIOS IN SALIVARY GLAND FNA DIAGNOSIS Fine needle aspiration (FNA) is a minimally invasive, cost-effective and well-tolerated approach for the preoperative differentiation of neoplastic (benign or malignant) and non-neoplastic lesions.1 The Milan system for reporting salivary gland cytopathology (MSRSGC) has helped to standardize cytology reporting thanks to the identification of diagnostic categories with different risks of malignancy (ROM) and relative...

Oct 31, 2023 | mdpi.com | Caterina de Luca |Francesco Pepe |Gianluca Russo |Mariantonia Nacchio

1. IntroductionIn recent decades, personalized medicine has laid the basis for a novel therapeutical option for solid-tumor patients [1,2]. Currently, target therapy is routinely available for the clinical administration of several solid-tumor patients, including metastatic colorectal cancer (mCRC), melanoma (MM), non-small cell lung cancer (NSCLC), gastrointestinal stromal tumor (GIST), and breast cancer (BC) patients [3,4,5,6,7,8,9].

Oct 20, 2023 | frontiersin.org | Francesco Pepe |Caterina de Luca |Baohua Sun |Kelly M. R

IntroductionLung cancer is one of the leading causes of cancer-related deaths in the world. (1) In the current era of precision medicine, non-small cell lung cancer (NSCLC) has a wide assortment of targeted therapies linked to genomic biomarkers and signatures. (2, 3) Progress in genomic analysis using next-generation sequencing (NGS) has enabled the comprehensive detection of multiple targetable alterations simultaneously from limited tumor tissue.

May 12, 2023 | frontiersin.org | Caterina de Luca |Walid Shalata |Hai Pan |Mirko Marabese

IntroductionLung adenocarcinoma is the most common type of non-small cell lung cancer, and conventional chemotherapy-based therapy has failed to significantly improve the prognosis of advanced patients. Targeted therapies based on driver genes significantly prolong patient survival. EGFR is the most common driver gene, and the most predominant mutant forms are EGFR p.L858R and 19del, which are called classical mutations.